metformin has been researched along with Recrudescence in 32 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effectiveness and safety of metformin in treating women with endometrial hyperplasia." | 8.95 | Metformin for endometrial hyperplasia. ( Atiomo, W; Clement, NS; Mulvaney, CA; Oliver, TR; Sanner, JR; Shiwani, H, 2017) |
| "Metformin toxicity is well known to cause lactic acidosis." | 7.88 | Recurrent hypoglycemia secondary to metformin toxicity in the absence of co-ingestions: a case report. ( Aldobeaban, S; Alshehri, AA; Mzahim, B, 2018) |
| "Metformin therapy in pregnant women with PCOS was associated with a significant reduction in the rate of early pregnancy loss." | 7.81 | Effect of metformin on early pregnancy loss in women with polycystic ovary syndrome. ( Al-Biate, MA, 2015) |
| "The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial." | 7.80 | Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. ( Bachmann, A; Becker, A; Faison, T; Fajkovic, H; Herman, M; Karakiewicz, PI; Kautzky-Willer, A; Kluth, LA; Lee, RK; Loidl, W; Lotan, Y; Pummer, K; Remzi, M; Rieken, M; Scherr, DS; Schramek, P; Seitz, C; Shariat, SF; Tewari, A; Xylinas, E, 2014) |
| "Metformin has been shown to prevent insulin therapy-induced body weight gain when used in combination with insulin." | 6.70 | Metformin does not adversely affect hormonal and symptomatic responses to recurrent hypoglycemia. ( Born, J; Fehm, HL; Fruehwald-Schultes, B; Kern, W; Oltmanns, KM; Peters, A; Sopke, S; Toschek, B, 2001) |
| "To determine the effectiveness and safety of metformin in treating women with endometrial hyperplasia." | 4.95 | Metformin for endometrial hyperplasia. ( Atiomo, W; Clement, NS; Mulvaney, CA; Oliver, TR; Sanner, JR; Shiwani, H, 2017) |
| "Metformin toxicity is well known to cause lactic acidosis." | 3.88 | Recurrent hypoglycemia secondary to metformin toxicity in the absence of co-ingestions: a case report. ( Aldobeaban, S; Alshehri, AA; Mzahim, B, 2018) |
| "Metformin therapy in pregnant women with PCOS was associated with a significant reduction in the rate of early pregnancy loss." | 3.81 | Effect of metformin on early pregnancy loss in women with polycystic ovary syndrome. ( Al-Biate, MA, 2015) |
| "The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial." | 3.80 | Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. ( Bachmann, A; Becker, A; Faison, T; Fajkovic, H; Herman, M; Karakiewicz, PI; Kautzky-Willer, A; Kluth, LA; Lee, RK; Loidl, W; Lotan, Y; Pummer, K; Remzi, M; Rieken, M; Scherr, DS; Schramek, P; Seitz, C; Shariat, SF; Tewari, A; Xylinas, E, 2014) |
| "Metformin was administered twice daily for 28 days in addition to vincristine, dexamethasone, PEG-asparaginase and doxorubicin (VXLD)." | 2.87 | A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxo ( Barredo, JC; Gill, J; Goldberg, J; Hale, GA; Leclerc, GM; Lee, JK; Lush, R; Reed, DR; Setty, B; Smith, T; Trucco, M, 2018) |
| "Metformin has been shown to prevent insulin therapy-induced body weight gain when used in combination with insulin." | 2.70 | Metformin does not adversely affect hormonal and symptomatic responses to recurrent hypoglycemia. ( Born, J; Fehm, HL; Fruehwald-Schultes, B; Kern, W; Oltmanns, KM; Peters, A; Sopke, S; Toschek, B, 2001) |
| " Although no studies have been performed, anti-tuberculosis treatment may also have to be prolonged or intensified in terms of regimen or drug dosage if DM is present." | 2.58 | Clinical management of combined tuberculosis and diabetes. ( Harries, AD; Hill, PC; Koesoemadinata, R; van Crevel, R, 2018) |
| "One of the medical treatments used in Cushing's disease is the somatostatin analogue pasireotide, which acts on adrenocorticotropic hormone (ACTH) secretion by the pituitary." | 2.49 | Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. ( Bertherat, J; Bisot-Locard, S; Borson-Chazot, F; Brue, T; Chanson, P; Cortet-Rudelli, C; Delemer, B; Reznik, Y; Tabarin, A; Vergès, B, 2013) |
| "The effects of type 2 diabetes mellitus (T2DM) medications on secondary prevention after acute coronary syndrome (ACS) remain unclear." | 1.56 | Recurrent cardiovascular events in patients with newly diagnosed acute coronary syndrome: Influence of diabetes and its management with medication. ( Asano, T; Komaru, Y; Suzuki, L; Takeuchi, T; Urayama, KY, 2020) |
| "Metformin treatment relieves the clinical symptoms, reduces the inflammatory reaction indexes and regulates the Treg/Th17 axis in patients with BD, suggesting the potential of metformin as a candidate medicine for treatment of BD." | 1.51 | [Efficacy and safety of metformin for Behcet's disease and its effect on Treg/Th17 balance: a single-blinded, before-after study]. ( Chenhong, L; Dan, L; Jianfei, C; Jianlong, G; Yan, S; Yong, C, 2019) |
| "Metformin has antineoplastic and cancer protective effects in vitro, sensitizing leukemia cells to chemotherapeutic agents, inducing apoptosis and cell cycle arrest." | 1.48 | [Effect of metformin added to chemotherapy on the survival of patients with acute lymphoblastic leukemia]. ( Centeno Cruz, F; Ceron Maldonado, R; Collazo Jaloma, J; Kassack Ipiña, JJ; Martínez Tovar, A; Miranda Peralta, E; Olarte Carrillo, I; Ramos Peñafiel, C; Rozen Fuller, E, 2018) |
| "A total of 543 rectal cancer patients who were treated with neoadjuvant chemoradiotherapy followed by radical surgery from January 2007 to December 2011 were reviewed." | 1.43 | Metformin enhances the response to radiotherapy in diabetic patients with rectal cancer. ( Cho, YB; Choi, DH; Huh, JW; Kim, HC; Lee, WY; Oh, BY; Park, HC; Park, YA; Park, YS; Yun, SH, 2016) |
| "In her fifth pregnancy, treatment for gestational diabetes mellitus with metformin was associated with a lowering effect on bile acids and liver enzymes, indicating a possible role for metformin in the management of obstetric cholestasis." | 1.43 | Managing Recurring Obstetric Cholestasis With Metformin. ( Ali, A; Elfituri, A; Shehata, H, 2016) |
| "Postpericardiotomy syndrome is a well-known complication after cardiac surgery." | 1.42 | Incidence and risk factors of postpericardiotomy syndrome requiring medical attention: The Finland postpericardiotomy syndrome study. ( Airaksinen, J; Gunn, J; Karjalainen, P; Kiviniemi, T; Lehto, J, 2015) |
| "We identified 4817 stroke patients with type 2 diabetes mellitus." | 1.38 | Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study. ( Horsdal, HT; Johnsen, SP; Mehnert, F; Rungby, J, 2012) |
| " Metformin, the first-line drug for diabetes, has low bioavailability and slow, incomplete gastrointestinal absorption." | 1.37 | Effect of gastric bypass surgery on the absorption and bioavailability of metformin. ( Birch, DW; Brocks, DR; Gabr, RQ; Karmali, S; Langkaas, LA; Padwal, RS; Sharma, AM, 2011) |
| " After reduction of the metformin dosage (500 mg twice daily) and discontinuance of exenatide as well as a reduction of his physical activity (because of joint pain) for six months, the glucose control worsened." | 1.36 | [Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes]. ( Kress, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (12.50) | 29.6817 |
| 2010's | 24 (75.00) | 24.3611 |
| 2020's | 4 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Komaru, Y | 1 |
| Takeuchi, T | 1 |
| Suzuki, L | 1 |
| Asano, T | 1 |
| Urayama, KY | 1 |
| McInnes, N | 1 |
| Hall, S | 1 |
| Sultan, F | 1 |
| Aronson, R | 1 |
| Hramiak, I | 1 |
| Harris, S | 1 |
| Sigal, RJ | 1 |
| Woo, V | 1 |
| Liu, YY | 1 |
| Gerstein, HC | 1 |
| Kopel, J | 1 |
| Grooms, A | 1 |
| Ganapathy, V | 1 |
| Clothier, J | 1 |
| Deshmukh, A | 1 |
| Ghannam, M | 1 |
| Liang, J | 1 |
| Saeed, M | 1 |
| Cunnane, R | 1 |
| Ghanbari, H | 1 |
| Latchamsetty, R | 1 |
| Crawford, T | 1 |
| Batul, SA | 1 |
| Chung, E | 1 |
| Bogun, F | 1 |
| Jongnarangsin, K | 1 |
| Pelosi, F | 1 |
| Chugh, A | 1 |
| Morady, F | 1 |
| Oral, E | 1 |
| Oral, H | 1 |
| Dutta, NK | 1 |
| Pinn, ML | 1 |
| Karakousis, PC | 1 |
| Clement, NS | 1 |
| Oliver, TR | 1 |
| Shiwani, H | 1 |
| Sanner, JR | 1 |
| Mulvaney, CA | 1 |
| Atiomo, W | 1 |
| Trucco, M | 1 |
| Barredo, JC | 1 |
| Goldberg, J | 1 |
| Leclerc, GM | 1 |
| Hale, GA | 1 |
| Gill, J | 1 |
| Setty, B | 1 |
| Smith, T | 1 |
| Lush, R | 1 |
| Lee, JK | 1 |
| Reed, DR | 1 |
| Aldobeaban, S | 1 |
| Mzahim, B | 1 |
| Alshehri, AA | 1 |
| Ramos Peñafiel, C | 1 |
| Olarte Carrillo, I | 1 |
| Ceron Maldonado, R | 1 |
| Miranda Peralta, E | 1 |
| Rozen Fuller, E | 1 |
| Kassack Ipiña, JJ | 1 |
| Centeno Cruz, F | 1 |
| Collazo Jaloma, J | 1 |
| Martínez Tovar, A | 1 |
| van Crevel, R | 1 |
| Koesoemadinata, R | 1 |
| Hill, PC | 1 |
| Harries, AD | 1 |
| Yong, C | 1 |
| Dan, L | 1 |
| Chenhong, L | 1 |
| Yan, S | 1 |
| Jianfei, C | 1 |
| Jianlong, G | 1 |
| Kibrik, P | 1 |
| Alsheekh, A | 1 |
| Izakovich, T | 1 |
| Chait, J | 1 |
| Goldstein, MA | 1 |
| Monteleone, CM | 1 |
| Hingorani, A | 1 |
| Ascher, E | 1 |
| Rieken, M | 1 |
| Kluth, LA | 1 |
| Xylinas, E | 1 |
| Fajkovic, H | 1 |
| Becker, A | 1 |
| Karakiewicz, PI | 1 |
| Herman, M | 1 |
| Lotan, Y | 1 |
| Seitz, C | 1 |
| Schramek, P | 1 |
| Remzi, M | 1 |
| Loidl, W | 1 |
| Pummer, K | 1 |
| Lee, RK | 1 |
| Faison, T | 1 |
| Scherr, DS | 1 |
| Kautzky-Willer, A | 1 |
| Bachmann, A | 1 |
| Tewari, A | 1 |
| Shariat, SF | 1 |
| Nicolle, LE | 1 |
| Capuano, G | 1 |
| Fung, A | 1 |
| Usiskin, K | 1 |
| Greenhill, C | 1 |
| Lehto, J | 1 |
| Gunn, J | 1 |
| Karjalainen, P | 1 |
| Airaksinen, J | 1 |
| Kiviniemi, T | 1 |
| Béjot, Y | 1 |
| Bielefeld, P | 1 |
| Guiboux, AL | 1 |
| Sgro, C | 1 |
| Janoura, S | 1 |
| Devilliers, H | 1 |
| Besancenot, JF | 1 |
| Giroud, M | 1 |
| Lefaucheur, R | 1 |
| Bourre, B | 1 |
| Ozkul-Wermester, O | 1 |
| Maltête, D | 1 |
| Wallon, D | 1 |
| Al-Biate, MA | 1 |
| Oh, BY | 1 |
| Park, YA | 1 |
| Huh, JW | 1 |
| Cho, YB | 1 |
| Yun, SH | 1 |
| Lee, WY | 1 |
| Park, HC | 1 |
| Choi, DH | 1 |
| Park, YS | 1 |
| Kim, HC | 1 |
| Elfituri, A | 1 |
| Ali, A | 1 |
| Shehata, H | 1 |
| Kress, S | 1 |
| Boehm, KM | 1 |
| Gunaga, S | 1 |
| Patel, T | 1 |
| Hruby, G | 1 |
| Badani, K | 1 |
| Abate-Shen, C | 1 |
| McKiernan, JM | 1 |
| Padwal, RS | 1 |
| Gabr, RQ | 1 |
| Sharma, AM | 1 |
| Langkaas, LA | 1 |
| Birch, DW | 1 |
| Karmali, S | 1 |
| Brocks, DR | 1 |
| Horsdal, HT | 1 |
| Mehnert, F | 1 |
| Rungby, J | 1 |
| Johnsen, SP | 1 |
| Panossian, Z | 1 |
| Drury, PL | 1 |
| Cundy, T | 1 |
| Reznik, Y | 1 |
| Bertherat, J | 1 |
| Borson-Chazot, F | 1 |
| Brue, T | 1 |
| Chanson, P | 1 |
| Cortet-Rudelli, C | 1 |
| Delemer, B | 1 |
| Tabarin, A | 1 |
| Bisot-Locard, S | 1 |
| Vergès, B | 1 |
| Heine, RJ | 1 |
| Diamant, M | 1 |
| Mbanya, JC | 1 |
| Nathan, DM | 1 |
| Mellbin, LG | 1 |
| Malmberg, K | 1 |
| Norhammar, A | 1 |
| Wedel, H | 1 |
| Rydén, L | 1 |
| Fruehwald-Schultes, B | 1 |
| Kern, W | 1 |
| Oltmanns, KM | 1 |
| Sopke, S | 1 |
| Toschek, B | 1 |
| Born, J | 1 |
| Fehm, HL | 1 |
| Peters, A | 1 |
| Lee, F | 1 |
| Patel, HR | 1 |
| Copland, P | 1 |
| Kahn, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga[NCT02561130] | Phase 4 | 154 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia[NCT05326984] | 20 participants (Anticipated) | Interventional | 2021-02-09 | Recruiting | |||
| METformin in Intrahepatic Cholestasis of Pregnancy (METRIC) Study[NCT03056274] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
| Study of the Concentrations of Long Acting Morphine After Oral Absorption in Subjects Who Underwent Gastric Bypass (OBEMO 2)[NCT02641301] | Phase 4 | 24 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(Waist circumference at 12 weeks - waist circumference at randomization) (NCT02561130)
Timeframe: 12 weeks after randomization
| Intervention | cm (Mean) |
|---|---|
| Intervention | -3.0 |
| Standard Care | -1.3 |
Expressed in Diabetes Control and Complications Trial (DCCT) units (NCT02561130)
Timeframe: 12 weeks after randomization
| Intervention | percentage of glycated hemoglobin (Mean) |
|---|---|
| Intervention | 5.9 |
| Standard Care | 6.6 |
Diabetes relapse without overt hyperglycemia is defined as HbA1C 6.5-6.9% off glucose-lowering agents for at least 12 weeks. (NCT02561130)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 20 |
| Standard Care | 9 |
Drug-free diabetes remission is defined as HbA1C < 6.5 % off glucose-lowering agents for at least 12 weeks. (NCT02561130)
Timeframe: 64 weeks after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 11 |
| Standard Care | 6 |
Drug-free diabetes remission is defined as HbA1C < 6.5 % off glucose-lowering agents for at least 12 weeks. (NCT02561130)
Timeframe: 24 weeks after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 19 |
| Standard Care | 13 |
Drug-free complete diabetes remission is defined as HbA1C < 6.0 % off glucose-lowering agents for at least 12 weeks. (NCT02561130)
Timeframe: 24 weeks after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 6 |
| Standard Care | 6 |
Symptomatic hypoglycemic episode is defined as an event with clinical symptoms consistent with hypoglycemia. (NCT02561130)
Timeframe: During 64 weeks of follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 34 |
| Standard Care | 15 |
Severe hypoglycemic episode is defined as an event with clinical symptoms consistent with hypoglycemia in which the participant required the assistance of another person, and one of the following: (i) the event was associated with a documented self-measured or laboratory plasma glucose level NCT02561130)
Timeframe: During 64 weeks of follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 0 |
| Standard Care | 0 |
(Weight at randomization - weight at 12 weeks)/(weight at randomization) (NCT02561130)
Timeframe: 12 weeks after randomization
| Intervention | percentage of weight loss (Mean) |
|---|---|
| Intervention | 2.9 |
| Standard Care | 1.0 |
4 reviews available for metformin and Recrudescence
| Article | Year |
|---|---|
Metformin for endometrial hyperplasia.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Disease Progression; Endometrial Hyperplasia; Female; | 2017 |
Clinical management of combined tuberculosis and diabetes.
Topics: Antitubercular Agents; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Me | 2018 |
Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide.
Topics: Biomarkers; Blood Glucose; Clinical Trials as Topic; Drug Therapy, Combination; Glycated Hemoglobin; | 2013 |
Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?
Topics: Algorithms; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin- | 2006 |
5 trials available for metformin and Recrudescence
| Article | Year |
|---|---|
Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug | 2020 |
A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxo
Topics: Adolescent; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Asparagin | 2018 |
Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozi | 2014 |
The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Epidemiologic Methods; Female; Humans; Hypoglycemic | 2008 |
Metformin does not adversely affect hormonal and symptomatic responses to recurrent hypoglycemia.
Topics: Adult; Area Under Curve; Autonomic Nervous System; Blood Glucose; Double-Blind Method; Glucose Clamp | 2001 |
23 other studies available for metformin and Recrudescence
| Article | Year |
|---|---|
Recurrent cardiovascular events in patients with newly diagnosed acute coronary syndrome: Influence of diabetes and its management with medication.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; F | 2020 |
Metformin, valproic acid, and starvation induce seizures in a patient with partial SLC13A5 deficiency: a case of pharmaco-synergistic heterozygosity.
Topics: Adult; Amino Acid Substitution; Ammonia; Animals; Anticonvulsants; Autistic Disorder; Bipolar Disord | 2021 |
Effect of metformin on outcomes of catheter ablation for atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Catheter Ablation; Female; Humans; Metformin; Middle Aged; Recurrence; Ri | 2021 |
Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice.
Topics: Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Drug Synergism; Drug Therapy | 2017 |
Recurrent hypoglycemia secondary to metformin toxicity in the absence of co-ingestions: a case report.
Topics: Acidosis, Lactic; Anti-Obesity Agents; Female; Humans; Hypoglycemia; Metformin; Polycystic Ovary Syn | 2018 |
[Effect of metformin added to chemotherapy on the survival of patients with acute lymphoblastic leukemia].
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; D | 2018 |
[Efficacy and safety of metformin for Behcet's disease and its effect on Treg/Th17 balance: a single-blinded, before-after study].
Topics: Behcet Syndrome; Controlled Before-After Studies; Forkhead Transcription Factors; Humans; Immunosupp | 2019 |
Does Metformin Have an Effect on Stent Patency Rates.
Topics: Aged; Constriction, Pathologic; Diabetes Mellitus, Type 2; Endovascular Procedures; Female; Femoral | 2019 |
Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer.
Topics: Aged; Diabetes Mellitus; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor | 2014 |
Gastric cancer. Metformin improves survival and recurrence rate in patients with diabetes and gastric cancer.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agent | 2015 |
Incidence and risk factors of postpericardiotomy syndrome requiring medical attention: The Finland postpericardiotomy syndrome study.
Topics: Aged; Body Mass Index; Chi-Square Distribution; Comorbidity; Diabetes Mellitus; Drainage; Erythrocyt | 2015 |
Recurrent encephalopathy induced by metformin in an elderly man.
Topics: Aged; Brain Diseases; Humans; Male; Metformin; Recurrence | 2015 |
Stroke mimicking relapse in a patient with CLIPPERS syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Brain Stem; Encephalomye | 2015 |
Effect of metformin on early pregnancy loss in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Adult; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndr | 2015 |
Metformin enhances the response to radiotherapy in diabetic patients with rectal cancer.
Topics: Aged; Case-Control Studies; Chemoradiotherapy; Diabetes Complications; Female; Humans; Hypoglycemic | 2016 |
Managing Recurring Obstetric Cholestasis With Metformin.
Topics: Adult; Bile Acids and Salts; Cholagogues and Choleretics; Cholestasis, Intrahepatic; Diabetes, Gesta | 2016 |
[Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes].
Topics: Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dru | 2010 |
Cimetidine-induced lactic acidosis and acute pancreatitis.
Topics: Acidosis, Lactic; Acute Disease; Cimetidine; Diabetes Mellitus, Type 2; Drug Interactions; Female; G | 2010 |
Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin.
Topics: Aged; Antineoplastic Agents; Diabetes Mellitus, Type 2; Disease-Free Survival; Humans; Hypoglycemic | 2010 |
Effect of gastric bypass surgery on the absorption and bioavailability of metformin.
Topics: Absorption; Adolescent; Adult; Area Under Curve; Biological Availability; Diabetes Mellitus; Female; | 2011 |
Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Denmark; Diabetes Mellitus, Type 2; Female; Follow-Up Studi | 2012 |
Reversible severe deterioration of glycaemic control after withdrawal of metformin treatment.
Topics: Aged; Aged, 80 and over; Contraindications; Diabetes Complications; Diabetes Mellitus, Type 2; Drug | 2012 |
Fowler's syndrome: cause or consequence of insulin resistance?
Topics: Adult; Electromyography; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycys | 2002 |